Zhigang Zhuang

机构：Kaiser Permanente, Sun Yat-sen University, Shanghai First Maternity and Infant Hospital · ORCID：0000-0002-7827-4402

发表论文 88 篇 · 总被引 1504 次 · h-index 21

代表论文

• Deciphering the prognostic significance of anoikis-related lncRNAs in invasive breast cancer: from comprehensive bioinformatics analysis to functional experimental validation. (2024 · PubMed · 被引 65)
• Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer (2023 · Nature Cancer · 被引 63)
• Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial (2024 · BMJ · 被引 15)
• Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial (2021 · The Lancet Regional Health - Western Pacific · 被引 14)
• Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4 (2025 · Journal of Biomedical Science · 被引 12)
• Adenosquamous carcinoma of the breast: a population-based study (2021 · Breast Cancer · 被引 8)